Liposomal Amikacin for Treatment of M. avium Infections in Clinically Relevant Experimental Settings

Ehlers, Stefan; Bucke, W.E.; Leitzke, S.; Fortmann, Leander; Smith, Debbie A.; Hänsch, H.C.R.; Hahn, Helmut; Bancroff, Gregory; Müller, Rainer H.

doi:10.1016/s0934-8840(96)80097-1

Cited by 14 publications

(13 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2). Thus, a once-weekly treatment schedule proved to be as effective as previously reported regimens of twiceweekly or even daily injections (3,6,8,9).…”

mentioning

confidence: 75%

“…Previous studies demonstrated the general usefulness of liposome-encapsulated drugs in murine models of M. avium infection (6)(7)(8)(9). To capitalize on these findings, the aims of our study were (i) to define suitable application intervals for intermittent therapy based on a pharmacokinetic evaluation of drug accumulation in infected organs and (ii) to establish whether intermittent therapy with prolonged application intervals would be effective in experimental M. avium infection.…”

mentioning

confidence: 99%

“…To test the therapeutic efficacy of once-weekly and once-monthly administration of 2,000 mg of liposomal amikacin during infection, C57BL/6 mice were inoculated intravenously with 10 5 CFU of the virulent M. avium strain TMC 724 (a gift from F. Collins, Trudeau Institute, Saranac Lake, N.Y.). Liposomal amikacin was given intravenously for 6 consecutive weeks or months, starting on day 7 after infection, and bacterial loads were monitored in the livers, spleens, and lungs of treated and untreated mice, as described previously (9,10). This model of infection was chosen because it leads to the death of even immunocompetent mice 120 to 150 days after infection (9).…”

mentioning

confidence: 99%

“…Liposomal amikacin was given intravenously for 6 consecutive weeks or months, starting on day 7 after infection, and bacterial loads were monitored in the livers, spleens, and lungs of treated and untreated mice, as described previously (9,10). This model of infection was chosen because it leads to the death of even immunocompetent mice 120 to 150 days after infection (9).…”

mentioning

confidence: 99%

See 3 more Smart Citations

Rationale for and Efficacy of Prolonged-Interval Treatment Using Liposome-Encapsulated Amikacin in Experimental Mycobacterium avium Infection

Leitzke

Bucke

Börner

et al. 1998

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The potential of liposome-encapsulated antibiotics for prolonging drug application intervals was investigated by using a murine model of chronic lethal Mycobacterium avium infection. Liposomal encapsulation of amikacin, but not of ciprofloxacin, resulted in high and sustained drug levels in infected tissues, exceeding the minimal inhibitory concentration for M. avium for at least 28 days. As a consequence, once-weekly and even once-monthly treatments with liposomal amikacin significantly reduced bacterial replication in infected tissues and extended the survival time of infected mice.

show abstract

“…2). Thus, a once-weekly treatment schedule proved to be as effective as previously reported regimens of twiceweekly or even daily injections (3,6,8,9).…”

mentioning

confidence: 75%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Rationale for and Efficacy of Prolonged-Interval Treatment Using Liposome-Encapsulated Amikacin in Experimental Mycobacterium avium Infection

Leitzke

Bucke

Börner

et al. 1998

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…They have permeability properties similar to those of biological membranes. Liposome administration has been shown to provide delivery of antibiotics in mice infected with Mycobacterium avium (2,8,10,12,15,24,25,27) or M. tuberculosis (9,26,36) with some success.…”

mentioning

confidence: 99%

Efficacy of Microencapsulated Rifampin in Mycobacterium tuberculosis -Infected Mice

Quenelle¹,

Staas²,

Winchester³

et al. 1999

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Rifampin is a first-line drug useful in the treatment of tuberculosis. By using biocompatible polymeric excipients of lactide and glycolide copolymers, two microsphere formulations were developed for targeted and sustained delivery of rifampin, with minimal dosing. A small-microsphere formulation, with demonstrated ability to inhibit intracellularly replicating Mycobacterium tuberculosisH37Rv, was tested along with a large-microsphere formulation in an infected mouse model. Results revealed that by using a single treatment of the large-microsphere formulation, it was possible to achieve a significant reduction in M. tuberculosis H37Rv CFUs in the lungs of mice by 26 days postinfection. A combination of small (given as two injections on day 0 and day 7) and large (given as one injection at day 0) rifampin-loaded microsphere formulations resulted in significant reductions in CFUs in the lungs by 26 days, achieving a 1.23 log10 reduction in CFUs. By comparison, oral treatment with 5, 10, or 20 mg of rifampin/kg of body weight, administered every day, resulted in a reduction of 0.42, 1.7, or 1.8 log10units, respectively. Thus the microsphere formulations, administered in one or two doses, were able to achieve results in mice similar to those obtained with a daily drug regimen within the range of the highest clinically tolerated dosage in humans. These results demonstrate that microsphere formulations of antimycobacterial drugs such as rifampin can be used for therapy of tuberculosis with minimal dosing.

show abstract

Nanotherapeutics for Bacterial Livestock Diseases

Kumar,

Banerjee,

Akshita

et al. 2024

Nanotechnology Theranostics in Livestock Diseases and Management

View full text Add to dashboard Cite

Liposomal Amikacin for Treatment of M. avium Infections in Clinically Relevant Experimental Settings

Cited by 14 publications

References 21 publications

Rationale for and Efficacy of Prolonged-Interval Treatment Using Liposome-Encapsulated Amikacin in Experimental Mycobacterium avium Infection

Rationale for and Efficacy of Prolonged-Interval Treatment Using Liposome-Encapsulated Amikacin in Experimental Mycobacterium avium Infection

Efficacy of Microencapsulated Rifampin in Mycobacterium tuberculosis -Infected Mice

Nanotherapeutics for Bacterial Livestock Diseases

Contact Info

Product

Resources

About